IOBT NASDAQ
IO Biotech, Inc.
1W: -33.2%
1M: -96.8%
3M: -98.8%
YTD: -99.1%
1Y: -99.3%
3Y: -99.7%
$0.01
Last traded 2026-04-20 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
8 relationships8
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2021-12-06
Earliest Filing
2023-08-07
Latest Filing
investor: 4
partner: 4
Counterparties (Filed by IOBT)
8 relationshipsCompanies named in IOBT's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Lundbeckfonden BioCapital | — | investor | Institutional investor purchasing common stock and warrants in private placement. | 2023-08-07 | View |
| Novo Holdings | NONOF | investor | Institutional investor purchasing common stock and warrants in private placement. | 2023-08-07 | View |
| Kurma Growth Opportunities Fund | — | investor | Institutional investor purchasing common stock and warrants in private placement. | 2023-08-07 | View |
| Sunstone Life Science Ventures | — | investor | Institutional investor purchasing common stock and warrants in private placement. | 2023-08-07 | View |
| Morgan Stanley & Co. LLC | MS-PL | partner | Joint placement agent for the private placement. | 2023-08-07 | View |
| Piper Sandler & Co. | PIPR | partner | Joint placement agent for the private placement. | 2023-08-07 | View |
| MSD International GmbH | — | partner | Partner in Clinical Trial Collaboration and Supply Agreement for Phase II trial of IO102/IO103 with pembrolizumab | 2021-12-06 | View |
| MSD International Business GmbH | — | partner | Partner in Clinical Trial Collaboration and Supply Agreement for Phase II trial of IO102/IO103 with pembrolizumab | 2021-12-06 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-03-31 | Officer/Director Change; Other Events | View | |
| 2026-02-13 | Notice of Delisting or Transfer | View | |
| 2026-01-30 | Costs Associated with Exit or Disposal Activities; Departure/Election of Directors; Appointment of O | View | |
| 2026-01-21 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-19 | Notice of Delisting or Transfer | View | |
| 2025-11-21 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-11-18 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-29 | Costs Associated with Exit or Disposal Activities; Regulation FD Disclosure; Other Events; Financial | View | |
| 2025-08-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-11 | Results of Operations and Financial Condition; Regulation FD Disclosure; Other Events; Financial Sta | View | |
| 2025-06-27 | Unregistered Sales of Equity Securities; Other Events; Financial Statements and Exhibits | View | |
| 2025-06-20 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-06-09 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-06-04 | Other Events; Financial Statements and Exhibits | View | |
| 2025-05-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-30 | Unregistered Sales of Equity Securities; Other Events; Financial Statements and Exhibits | View | |
| 2025-03-04 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2024-12-27 | Notice of Delisting or Transfer | View | |
| 2024-12-20 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR